title: Relationship between neointimal coverage of sirolimus-eluting stents and lesion characteristics: a study with serial coronary angioscopy.
abstract: BACKGROUND
  Delayed neointimal coverage after the implantation of a drug-eluting stent (DES) is thought to be related to their potential for developing late-stent thrombosis. However, few studies have shown which factor affects the neointimal coverage after DES implantation. We hypothesized that the extent of neointimal coverage after DES implantation is affected by the underlying lesion characteristics because arterial wall components are reported to determine the transport and distribution of the drugs.
  
  
  METHODS
  Thirty-seven coronary artery lesions treated with a single sirolimus-eluting stent (SES) were evaluated in 37 patients with stable coronary artery disease. Angioscopy was performed before, immediately after, and 6 months after stenting to examine the existence of yellow plaque, thrombus, complex plaque, and intramural hemorrhage and the degree of neointimal coverage at 6-month follow-up. This was classified either as a noncoverage group (stent struts were predominantly exposed or visible through a thin neointima) or as a coverage group (stent struts were predominantly covered by neointimal hyperplasia and thus invisible).
  
  
  RESULTS
  Twenty-one lesions were classified into the noncoverage group, and 16 lesions the coverage group. The frequency of preexistent yellow plaques was significantly higher in the noncoverage group than that in the coverage group (67% vs 19%, P = .007). A multivariate logistic regression analysis showed the preexistence of yellow plaque was the only independent factor behind less neointimal coverage at 6 months after SES implantation (odds ratio 19.5, 95% confidence interval 1.58-240.50, P = .020).
  
  
  CONCLUSIONS
  The preexistence of yellow plaque may be associated with decreased neointimal coverage of SES.
authors.affiliation: Cardiovascular Center, Nippon Medical School, Chiba Hokusoh Hospital, 1715 Kamakari, Inba, Inba, Chiba, Japan.
authors.forename: Masanori
authors.initials: M
authors.lastname: Yamamoto
authors.forename: Kentaro
authors.initials: K
authors.lastname: Okamatsu
authors.forename: Shigenobu
authors.initials: S
authors.lastname: Inami
authors.forename: Masamichi
authors.initials: M
authors.lastname: Takano
authors.forename: Shinya
authors.initials: S
authors.lastname: Yokoyama
authors.forename: Takayoshi
authors.initials: T
authors.lastname: Ohba
authors.forename: Chikao
authors.initials: C
authors.lastname: Ibuki
authors.forename: Noritake
authors.initials: N
authors.lastname: Hata
authors.forename: Yoshihiko
authors.initials: Y
authors.lastname: Seino
authors.forename: Kyoichi
authors.initials: K
authors.lastname: Mizuno
mesh_terms: D000368:Aged; D017546:Angioscopy; D017023:Coronary Angiography; D003324:Coronary Artery Disease / Q000473:pathology / Q000628:therapy*; D023903:Coronary Restenosis / Q000175:diagnosis* / Q000473:pathology; D003331:Coronary Vessels / Q000473:pathology*; D054855:Drug-Eluting Stents; D019544:Equipment Failure Analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D012307:Risk Factors; D020123:Sirolimus / Q000008:administration & dosage*; D017539:Tunica Intima / Q000473:pathology*
chemical_list: D020123:Sirolimus